The Union World Conference will hold a series of Meet The Expert sessions, consisting of a short live talk followed by a discussion. These are included in the main conference programme. So far the following MTE sessions are confirmed:
09:45-10:45 CEST: TB vaccine for children.
Presenter: Elisa Nemes (South Africa)
Dr Nemes completed her PhD in HIV-specific T cell immunology in Italy and France. She then worked on paediatric immune responses to HIV and tuberculosis in Cameroon. She joined the South African Tuberculosis Vaccine Initiative in 2011, where she is involved in the scientific supervision of clinical trials of new tuberculosis vaccines, development of immunodiagnostics and basic immunological studies on adaptive and innate immunity to M. tuberculosis in HIV infected and uninfected children, adolescents and adults. Dr Nemes is centrally involved in collaborative projects aimed at defining immune correlates of protection from M. tuberculosis infection and tuberculosis disease.
18:15-19:45 CEST: The use of technology to deliver care and treatment (communication, patient education, treatment adherence). How we can use technology, to have also remote, support to patients, during special times? And how can we learn from this, also for the general time?
Presenters: Bruce V Thomas (United States), Kateryna Gamazina (Ukraine)
Re-Imagined, Person-Centered Care: The Future is Now. In high-burden regions across the world, health outcomes from treatable, curable, or preventable disease remain sub-optimal. In addition, major gaps and delays exist at every step in the care cascade, and person-centered care is the exception and not the rule. The good news – the desire to “re-imagine” TB, HIV, dengue, and other care is, thanks to COVID-19, higher than ever. The even better news – across disease states and across every step in the patient journey, there are myriad existing/emerging, affordable, scalable, proven-effective digital health technologies that can enable such re-imagined, virtual, person-centered care. Let’s talk about what has happened (including recent, real world experience from Ukraine), is happening, and needs to happen to make that vision reality.
Kateryna Gamazina’s Bio: Dr. Kateryna Gamazina is an infection disease and public health specialist who for the past 15 years has served as PATH’s Country Leader in Ukraine. She is a Director of ASCENT project in Ukraine and previously was a Director for a Challenge TB/Ukraine project. Under her leadership, PATH has made significant progress in introducing and expanding TB control innovations in Ukraine. She has managed numerous social science and biomedical research studies. In addition, she regularly consults with other PATH country programs around the world on TB and HIV strategic planning and program implementation.
Bruce V Thomas’ Bio: Bruce Thomas is the Founder & Managing Director of The Arcady Group. He is a visionary leader, a recognized expert in the fields of medication adherence, digital health technologies, and innovation delivery and scale-up and a highly successful leader of, and adviser to, purpose-driven businesses. As both a consultant and grantee to the Bill & Melinda Gates Foundation, Bruce (i) leads the development, testing, and scale-up of new approaches to improve adherence and support differentiated care for TB and HIV patients in India, China, and Africa, (ii) assists in the scale-up of innovative approaches like the World Mosquito Program’s Wolbachia method to control dengue, zika, and other vector-borne diseases, and (iii) supports the work of the Gates Foundation-funded Medicines for All Institute in developing and scaling new manufacturing approaches and processes to reduce the cost of, and improve access to, essential global health treatments. Bruce has also consulted to Novartis, UNITAID, USAID, and the Stop TB Partnership on matters relating to digital health technologies and their potential use in enhancing patient management and improving health outcomes. Previously, as President of MWV Healthcare, a $7B global packaging company, he led the establishment of a proprietary manufacturing system and supply chain to bring generic pharmaceutical products to North America in ready-to-dispense, adherence-enhancing packaging in support of Walmart’s breakthrough $4 generic program.
09:45-10:45 CEST: BCG protection against COVID-19.
Presenter: Carolina Barillas-Mury (USA)
Dr. Barillas received her B.S. in biology from the Universidad del Valle de Guatemala in 1981, her M.D. from Universidad Francisco Marroquín de Guatemala in 1985, and her Ph.D. in biochemistry from the University of Arizona in 1992. From 1992 to 1993, she did postdoctoral training at the University of Arizona. She then went to Harvard University in 1994 and the European Molecular Lab until 1998. She was an assistant professor in the department of microbiology, immunology, and pathology at Colorado State University from 1998 to 2003. She joined the Laboratory of Malaria and Vector Research in 2003 and became a senior investigator in 2010.
18:15-19:15 CEST: The external quality assessment of Cepheid GeneXpert® diagnostic assays.
Presenters: Heidi Albert (South Africa), Patricia Hall (United States) and Tarak Shah (India)
GeneXpert networks pose unique challenges for quality assurance efforts from National TB Programs and reference laboratories (RLs), as they are expansive and flexible in their geography, number, patient population and test type. This session brings together three experts in international GeneXpert-based External Quality Assessment (EQA) with a range of experience from EQA guidance and tool development to national and multi-country program design, introduction and management. Participants will engage with experts to review what ‘EQA’ really means, learn what is practically needed to implement an EQA program and discuss challenges and opportunities associated with EQA programme administration in the era of COVID-19.
Tarak Shah’s Bio: Dr. Tarak Shah is working as a Medical Officer with FIND to support access initiatives for TB diagnostics. He is supporting India’s National TB Program to scale up one of the largest external quality assurance (EQA) program for GeneXpert testing in the world. Besides EQA for molecular testing, he has lead several lab projects of FIND such as establishing TB Culture and DST laboratories, strengthening quality management systems (QMS) for TB Labs to achieve ISO 15189 accreditation, Laboratory Information Management System, e- learning tools, bio-safety and more. Besides TB, he has keen interest in Anti-Microbial Resistance and health systems strengthening.
Patricia Hall’s Bio: Dr. Patricia Hall leads the TB and Clinical Monitoring Team (International Laboratory Branch) at US CDC, manages a WHO Supranational TB Reference Laboratory (Atlanta, GA USA) and serves as Vice Chair of the Stop TB Partnership’s Global Laboratory Initiative. She holds a PhD in Microbiology and Molecular Genetics from Emory University and a Master of Science in Evolutionary Development. Patricia leverages 17 years of laboratory research and project management experience to oversee a GeneXpert-based proficiency testing program across 24 countries, development of quality assurance (QA) practical guidance and tools and review TB/HIV quality assurance performance in PEPFAR-supported countries.
Heidi Albert’s Bio: Dr. Heidi Albert is Head of FIND South Africa and part of FIND’s Access team, supporting Ministries of Health to introduce and scale up new diagnostic tools. She holds a PhD in Pharmacy and Pharmacology from the University of Bath, UK, and a Masters in Public Health specializing in Health Economics from the University of Cape Town, South Africa. She has 20 years’ experience in TB diagnostics development, implementation and quality improvement in low and middle income countries. She served on the Global Laboratory Initiative (GLI) core group from 2014-2018, and has been a lead contributor to multiple global and national TB diagnostic guidelines and tools, including several focusing on quality assurance. She currently leads work on data-driven diagnostic network optimization to inform national strategic planning and donor investment for TB, HIV and other diseases.
09:45-10:45 CEST: Health and well-being post TB.
Presenter: Jeremiah Chakayah (Kenya)
Successful outcome of tuberculosis (TB) care and treatment is currently based on cure (laboratory evidence of mycobacterial eradication from the site of disease) and or completion of drug treatment. For many people who suffer an episode of TB, successful treatment of TB means a return to good health with no symptoms, no limitation of activity and no long term psychological consequences. However a significant but variable proportion of people who experience an episode of TB, life is never the same with persistence of symptoms and progressive limitation of physical activity, which leads to inability to work and is thus impoverishing and with major consequences on quality of life. This session will summarise the burden of post-TB chronic disease with an emphasis on the lung and discuss measures that may be undertaken to prevent, identify and provide care to those who suffer post chronic lung disease.
Bio: Dr. Jeremiah Chakaya hails from Kenya where he was born, educated and practices and teaches respiratory medicine. He graduated from the University of Nairobi with a basic degree in medicine and surgery (MBChB) in 1985 and a master’s degree in internal medicine (M.Med) in 1992. He then went on to study lung medicine at the National Lung and Heart Institute, University of London at the Royal Brompton Hospital and at the Kyorin University Hospital in Tokyo, Japan. Dr Chakaya worked as a TB and Lung disease researcher at the Centre for Respiratory Diseases Research and later served as the TB Program Manager at the Ministry of Health between 2003 and 2006. At the international level, Dr Chakaya has held several positions including, Vice Chair of the Stop TB Partnership Coordinating Board, Chair of the Strategic and Technical Advisory Group for TB (STAG-TB ) of the World Health Organization (WHO), Chair of the Global Fund’s Technical Review Panel (TRP) and President of the International Union Against Tuberculosis and Lung Disease (The Union). Dr Chakaya is a founder member of the Respiratory Society of Kenya (ReSoK) and has remained closely engaged with this organization. He is a member of the Pan African Thoracic Society and serves in the executive committee of this organisation. In April 2020 he took up a position as Professor for Global Respiratory Health at the Liverpool School of Tropical Medicine in the United Kingdom. He teaches on a voluntary basis at the school of medicine, Kenyatta University, after many years of work with the Kenya Medical Research Institute.
18:15-19:15 CEST: Clinical management of COVID-19.
Presenter: Carlos del Rio (USA)
09:45-10:45 CEST: Impact of COVID-19 on TB: what is happening in Europe?
Presenter: Giovanni Battista Migliori (Italy)
The session will start with a brief overview of Prof. Migliori’s career focused on the events and the opportunities which directed it towards the fight against TB. Participants are encouraged to interact and pose questions relevant for their career development.
The second part of the session will be devoted to discuss TB and COVID in Europe. Specific questions will be posed, and participants will be invited to respond and discuss the main issues around the topic.
The preliminary results of an ongoing TB and COVID-19 study will be used to answer, by the extent possible, the questions posed and to open a window on future developments.
Prof. Giovanni Battista Migliori, MD, FRCP (London), FERS, FAPSR
Specialist in Respiratory Medicine and Medical Statistics, and Auditor of Quality Systems, with >30 years of work supporting National TB Programmes in all continents, he is Director of the WHO Collaborating Centre for TB and Lung Diseases at Maugeri Foundation, Tradate, Italy, active in TB control, training and research.
Hon. Prof. at the Queen Mary University, London, he has published >550 peer-review papers on TB and respiratory diseases (H-index 68; >18,000 citations) in different languages (English, Spanish, Portuguese and Russian), including the latest guidelines of WHO, ECDC and ATS/IDSA/ERS/CDC.
He is currently Chief Editor of the International Journal of Tuberculosis and Lung Disease, Section Editor of the European Respiratory Journal, and Associate Editor of Pulmonology and of the Jornal Brasileiro de Pneumologia.
Former Secretary General of the ERS, President of the UNION (European Region) and member of WHO STAG (the WHO technical advisory group), he is chair of the GTN (Global Tuberculosis Network).